Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2001

View Archived Issues

Thiazolinediones may provide therapeutic benefits in demyelinating diseases

Research grant awarded for isolating potential anticancer agents from mushrooms

Atugen enters evaluation agreement with Byk Gulden

Paradigm and StemCo collaborate on biochemical profiling of adult human stem cells

Bayer enters postgenomics collaboration

AERx iDMS at least as effective as subcutaneous insulin in type 2 diabetics

Antitumor effects of COX-2-specific inhibitor JTE-522 described at Japanese meeting

Exelixis to acquire Genomica

Phase II study initiated for ISIS-104838 in rheumatoid arthritis

Virulizin enters phase III for treatment of pancreatic cancer

Shire acquires license to compound for Parkinson's disease

Oxford GlycoSciences and Teva sign agreement for Vevesca in Israel

Various presentations at Oxygen Society meeting highlight broad-spectrum potential of SOD mimetics

Antisense inhibitor of HCV yields encouraging preliminary results in chronically infected patients

Pharmacokinetic and safety analyses of phase I Heptazyme trial in HCV presented at AASLD

Breakthrough treatment for severe sepsis approved for the first time

Inhibition of IL-6 binding produces clinical improvement in RA

Investigational anti-TNF antibody improves clinical measures of RA and joint destruction

Regeneron proceeds to phase II trials with IL-1 Trap following promising phase I findings

HIV protease inhibitors claimed in recent patent by Pharmacor team

Merck reports new MC4 receptor agonists and potential uses for these compounds

Two Pharmacia patents cover novel antiviral agents particularly useful against herpesviruses

Alcon identifies several related series of antiglaucoma agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...